895TiP - A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
| Autor: | Tran, B., Kouros-Mehr, H., Fermin, A., Horvath, L., Roncolato, F., Rettig, M., Dorff, T., Tagawa, S.T., Subudhi, S.K., Antonarakis, E.S., Armstrong, A.J., Petrylak, D.P., Fizazi, K., Salvati, M.E., Scher, H.I. |
|---|---|
| Zdroj: | In Annals of Oncology October 2019 30 Supplement 5:v353-v353 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|